Ling Xu
Directeur/Membre du Conseil chez Arctic Vision (Shanghai) Biotechnology Co., Ltd.
Profil
Ling Xu is currently the Director at Arctic Vision (Shanghai) Biotechnology Co., Ltd.
and a Board Member at Regor Therapeutics Group.
Previously, Ms. Xu worked as a Venture Partner at Loyal Valley Capital Co. Ltd.
Ms. Xu graduated from Fudan University with a graduate degree in 2002 and holds an undergraduate degree from Renmin University of China.
Postes actifs de Ling Xu
| Sociétés | Poste | Début |
|---|---|---|
Arctic Vision (Shanghai) Biotechnology Co., Ltd.
 Arctic Vision (Shanghai) Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a Chinese Shanghai-based ophthalmic biotech company that focuses on developing innovative therapies to address unmet clinical needs and benefit ophthalmic patients. The company is led by an elite team of ophthalmic industry veterans with substantial experience in R&D and commercialization of eye care products. Arctic Vision has top-tier biotech venture capital investors with a broad network in both the U.S. and European ophthalmic markets, and an unprecedented track record in company incubation. The company was founded by Hai Di Hu, who has been the CEO since incorporation. | Directeur/Membre du Conseil | 01/03/2021 |
Regor Therapeutics Group
 Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | Directeur/Membre du Conseil | 01/02/2021 |
Anciens postes connus de Ling Xu
| Sociétés | Poste | Fin |
|---|---|---|
Loyal Valley Capital Co. Ltd.
 Loyal Valley Capital Co. Ltd. Investment ManagersFinance Loyal Valley Capital Co. Ltd (LVC) is a private equity firm founded in 2015 by Li Jun Lin. The firm is headquartered in Shanghai, China. | Private Equity Investor | 01/12/2022 |
Formation de Ling Xu
| Fudan University | Graduate Degree |
| Renmin University of China | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Loyal Valley Capital Co. Ltd.
Loyal Valley Capital Co. Ltd. Investment ManagersFinance Loyal Valley Capital Co. Ltd (LVC) is a private equity firm founded in 2015 by Li Jun Lin. The firm is headquartered in Shanghai, China. | Finance |
Arctic Vision (Shanghai) Biotechnology Co., Ltd.
Arctic Vision (Shanghai) Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a Chinese Shanghai-based ophthalmic biotech company that focuses on developing innovative therapies to address unmet clinical needs and benefit ophthalmic patients. The company is led by an elite team of ophthalmic industry veterans with substantial experience in R&D and commercialization of eye care products. Arctic Vision has top-tier biotech venture capital investors with a broad network in both the U.S. and European ophthalmic markets, and an unprecedented track record in company incubation. The company was founded by Hai Di Hu, who has been the CEO since incorporation. | Health Technology |
Regor Therapeutics Group
Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | Commercial Services |
